Full-Time

Senior Scientist/Engineer

Medical Device and Combination Products, Analytical

Posted on 4/9/2025

Merck

Merck

10,001+ employees

Develops medicines and vaccines for health issues

No salary listed

Senior

H1B Sponsorship Available

North Wales, PA, USA

Hybrid work model consisting of three total days on-site per week, Monday - Thursday, with Friday designated as a remote-working day.

Category
Bioinformatics
Computational Biology
Genomics
Public Health
Biology Lab & Research
Diagnostics & Laboratory Professionals
Healthcare Administration & Support
Nursing & Allied Health Professionals
Physicians & Surgeons
Veterinary Professionals
Medical, Clinical & Veterinary
Biology & Biotech
Requirements
  • Ph.D. in Biomedical Engineering, Chemical Engineering, Mechanical Engineering, Materials Science & Engineering, or closely related field.
  • Demonstrated record of experimental research and publication in peer-reviewed journal(s)
Responsibilities
  • Define and deliver impactful science to our MDCP portfolio programs in both late-stage development and commercial manufacturing in the context of characterization, design verification, technical risk assessment, changes, and investigations.
  • Represent the CPDA on cross functional teams effectively as a trusted collaborator, clear communicator (verbal and written) and analytical technical leader, who asks critical questions to help define direction and takes actions to deliver.
  • Innovate and improve our analytical approaches to interrogate critical functionality, geometry and function and failure modes relevant to manufacturing, packaging, distribution or patient/provider use.
  • Deliver sharp problem solving through theoretical & experimental acumen [breadth and depth] and creative thinking.
  • Recognize technology gaps and drive to industry-leading fundamental understanding, as needed, in the realm of engineered materials, component/device designs, and function through depth in areas such as tribology, solid-mechanics, advanced material science, mechanical simulation and human factor studies.
  • Broaden and deepen your technical proficiency through learning and collaboration within the full CPDA, which includes primary packaging & protective packaging technology responsibilities, and our embedded sister group, which is a comprehensive physical materials science laboratory supporting (bio)pharmaceutical drug product commercialization and manufacturing.
Desired Qualifications
  • Proficiency with applied mechanical testing and material imaging. Advanced examples would be ability to develop non-standard methods for multi-axis multi-phase mechanical characterization and quantitative optical or x-ray tomographic imaging for precise dimensioning.
  • Medical device development with practical understanding of Design Controls (21 CFR 820.30) and relevant industry standards.
  • Proficiency in Device Characterization, for functionality and robustness.
  • Design Verification strategy & execution with respect to selection, development & validation of methods as well as principled design of stability studies, acceptance criteria and protocols.
  • Successful interdisciplinary research or manufacturing team projects.
  • Research involving solid mechanics or tribology, engineering/ processing of polymers, ceramics or glass, advanced material science, or mechanical simulation.

Merck develops medicines and vaccines to address significant health challenges such as cardiovascular disease, diabetes, and cancer. The company conducts extensive research and development to create new treatments, focusing on the pharmaceutical and biotechnology sectors. Merck generates revenue through the sale of prescription medications, vaccines, and animal health products. A key aspect of Merck's approach is its commitment to patient assistance programs, which provide free medicines and vaccines to eligible patients. Additionally, Merck supports healthcare professionals with resources like Merck Connect and Merck Manuals, distinguishing itself from competitors by its comprehensive support for both patients and healthcare providers.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kenilworth, Illinois

Founded

1891

Simplify Jobs

Simplify's Take

What believers are saying

  • Positive Phase 3 results for pembrolizumab suggest new cancer treatment opportunities.
  • Kinase inhibitors' use in autoimmune diseases offers Merck portfolio diversification.
  • Merck's digital health innovation leadership strengthens its competitive position.

What critics are saying

  • Data privacy concerns may arise from AI integration in healthcare settings.
  • Oral peptide delivery faces scientific and regulatory challenges.
  • Intensifying competition from companies like Novartis may impact Merck's market share.

What makes Merck unique

  • Merck's collaboration with Microsoft enhances clinical workflows using AI in healthcare.
  • The Cyprumed deal aims to make peptide drugs orally available, improving patient experience.
  • Merck's investment in vaccine manufacturing aligns with rising global vaccine demand.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Holidays

Paid Vacation

Paid Sick Leave

Hybrid Work Options

Flexible Work Hours

Company News

Healthcare Dive
Apr 16th, 2025
Merck Manuals Integrates Medical Reference Within Microsoft Copilot Studio

This collaboration exemplifies a commitment to enhancing clinical workflows by incorporating Merck Manuals' authoritative content into Microsoft's healthcare agent service in Copilot Studio.

Sandra Gona
Apr 16th, 2025
India logs 2,430 new Covid cases_Spider information

As a result of these efforts, Merck has been recognized as a "Digital Health Innovation Leader" for two consecutive years since 2023.

BioSpace
Apr 15th, 2025
Merck Eyes Oral Peptide Delivery With Cyprumed Deal Worth up to $493M

Merck on Tuesday entered into a nonexclusive licensing and option pact with Austrian biotech Cyprumed in a bid to make its peptide drugs orally available.

PR Newswire
Apr 14th, 2025
Merck Manuals To Collaborate With Microsoft To Integrate Medical Information Resources Into Healthcare Agent Service In Microsoft Copilot Studio

RAHWAY, N.J., April 14, 2025 /PRNewswire/ -- The Merck Manuals is pleased to announce its collaboration with Microsoft to integrate its esteemed professional medical reference into healthcare agent service in Microsoft Copilot Studio. This exciting initiative harnesses the power of Generative AI (GenAI) to provide clinicians with trusted, comprehensive, and evidence-based medical content at the point of care.The Merck Manuals is proud to be an independent (non-government) medical information resource integrated into this platform. This collaboration exemplifies a commitment to enhancing clinical workflows by incorporating Merck Manuals' authoritative content into Microsoft's healthcare agent service in Copilot Studio. This integration empowers healthcare technology developers to create generative AI-driven healthcare agents that leverage this high-value content to grant clinicians immediate access to vital medical information."Clinicians and healthcare organizations worldwide depend on the Merck Manuals and MSD Manuals for accurate and reliable answers to their clinical questions," stated Dr. Sandy Falk, Editor-in-Chief of the Merck Manuals. "Through this collaboration with Microsoft, we are building solutions to deliver our comprehensive, evidence-based content to meet the needs of healthcare professionals

APP
Apr 14th, 2025
Novartis plans $23B expansion of manufacturing in US, including North Jersey site

Merck announced plans to spend $1 billion on a vaccine manufacturing site in North Carolina, plus $8 billion on other upgrades.

INACTIVE